Supported By AstraZeneca
Room 20D, San Diego Convention Center

Program Description

Therapy using antibody-drug conjugates has been an important shift in the management of non-small cell lung cancer, allowing clinicians to capitalize on novel cell surface targets for patient benefit. However, optimal patient selection and management of adverse events remain key challenges for the use of these therapies.

This live, hybrid symposium is designed to bring together expert faculty in the development and use of antibody-drug conjugate treatments for non-small cell lung cancer for a discussion of cases highlighting key challenges and potential solutions for patients in this setting. Participants will have the opportunity to ask questions of the faculty directly and learn more about how this field of treatment is continuing to evolve.

Speakers

Jacob Sands, MD
Program Chair
Dana-Farber Cancer Institute
Assistant Professor
Boston, MA

Myung-Ju Ahn, MD
Professor
Sungkyunkwan University School of Medicine
Department of Medicine
Professor
Seoul, South Korea